Rectify Pharma (@RectifyPharma) header
Rectify Pharma (@RectifyPharma) profile picture

Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein function and address the underlying cause of serious diseases.

Boston, MA
Joined September 2021
#NEWS: Chronic kidney disease impacts ~1 in 10 adults (~850 million people). Together with @RectifyPharma, we’re targeting underlying disease mechanisms linked to calcification and cardiorenal risk. Learn more at go.boehringer.com/mPnXJ #ResearchCollaboration #CKD
3
2
1
9
1,119
Rectify Pharma retweeted
With a $100M series A co-led by Atlas Venture, Omega Funds, Forbion and Longwood Fund, Rectify is developing personalized therapies to restore ABC transporter function in multiple organs. An Emerging Company Profile by BioCentury's @DanielleGolovin buff.ly/3C1qPuG